Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136037 | 1.00 | ADA (0.61) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL3345754 | 0.91 | ADA (0.60) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL5064838 | 0.89 | ADA (0.60) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL772296 | 0.89 | ADA (0.63) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL8861820 | 0.89 | ADA (0.56) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL899393 | 0.88 | ADA (0.58) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL288325 | 0.88 | ADA (0.58) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL8000695 | 0.88 | ADA (0.58) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL5555999 | 0.88 | ADA (0.63) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL13727118 | 0.85 | ADA (0.55) | ADAALDH1A1TP53HTTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10376515-B2 | Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activating enzyme ATG7 | NORTHWESTERN UNIVERSITY (US) | 2019-08-13 | — | — | US | disclosed |
| US-20170312284-A1 | ANALOGS OF ADENOSINE MONOPHOSPHATE (AMP) AS INHIBITORS OF UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME ATG7 | NORTHWESTERN UNIVERSITY (US) | 2017-11-02 | — | — | US | disclosed |
| US-20110158922-A1 | Skin Care Compositions and Method of Use Thereof | IMMANENCE INTEGRALE DERMO CORRECTION INC. (CA) | 2011-06-30 | — | — | US | disclosed |
| EP-2262469-A1 | SKIN CARE COMPOSITIONS AND METHODS OF USE THEREOF | Immanence Integrale Dermo Correction Inc. (CA) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009127058-A1 | SKIN CARE COMPOSITIONS AND METHODS OF USE THEREOF | IMMANENCE INTEGRALE DERMO CORRECTION INC. (CA) | 2009-10-22 | — | — | WO | disclosed |
| US-5658889-A | ADMINISTERING 5-AMINO-4-IMIDAZLECARBOXAMIDE RIBOSIDE WHICH BINDS ADENOSINE MONOPHOSPHATE SITE OF FRUCTOSE-1,6-DIPHOSPHATASE | GENSIA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5082829-A | 5-amino-4-imidazolecarboxamide riboside to increase adenosine concentration, cardiovascular, seizures | GENSIA PHARMACEUTICALS (US) | 1992-01-21 | — | — | US | disclosed |
| EP-0427799-A4 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE | — | 1991-07-24 | — | — | EP | disclosed |
| EP-0427799-A1 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE. | GENSIA PHARMA (US) | 1991-05-22 | — | — | EP | disclosed |
| WO-1990009163-A2 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE | GENSIA PHARMACEUTICALS, INC. (US) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10376515-B2 | Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activating enzyme ATG7 | ATG7, BECN1, PRKAG1 | ADA 93/4885ALDH1A1 2810/4885TP53 107/4885 |
| US-20170312284-A1 | ANALOGS OF ADENOSINE MONOPHOSPHATE (AMP) AS INHIBITORS OF UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME ATG7 | ATG7, BECN1, PRKAG1 | ADA 93/4885ALDH1A1 2810/4885TP53 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.